Patent US5336598A successfully refreshed from Google Patents.
US5336598A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for diagnosing a superantigen caused pathologial condition via assay of T-cells
Assignee: National Jewish Health
•
Filing: 1989-11-15
•
Granted: 1994-08-09
•
Expires: 2009-11-15
Abstract
Abstract The invention teaches a method for determining levels of T-cell surface antigens in humans, specifically, V beta molecules. Measurement of such levels allows for diagnosis of pathological conditions, such as infections, where changes in these levels are indicative of a superantigen initiated pathological condition.
Inventors
- 👤 Brian L. Kotzin
- 👤 Philippa Marrack
- 👤 John Kappler
- 👤 Youngwon Choi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 17:20
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56966; G01N33/56972; C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6881; C12Q1/6883; C12Q1/6844; C12Q1/686; C12Q2600/00; C12Q2600/142; C12Q2600/158
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
70 words
A method for diagnosing a pathological condition caused by a superantigen, comprising assaying a T-cell containing body fluid sample of a human patient to determine the level of a Vβ elements characteristic of said pathological condition, and comparing the level to normal levels in a comparable T-cell containing body fluid sample, wherein a depletion of said Vβ element is indicative of a pathological condition caused by exposure to said superantigen.
Claim 2
Independent Claim
70 words
A method for diagnosing a pathological condition caused by a superantigen, comprising assaying a T-cell containing body fluid sample of a human patient to determine the level of a Vβ elements characteristic of said pathological condition, and comparing the level to normal levels in a comparable T-cell containing body fluid sample, wherein a depletion of said Vβ element is indicative of a pathological condition caused by exposure to said superantigen.
Claim 3
Independent Claim
41 words
A method for diagnosing a superantigen-mediated pathological condition, comprising assaying a T-cell containing body fluid sample of a human patient to determine the pattern of Vβ elements present, and identifying the presence of a superantigen-mediated pathological condition from said Vβ pattern.
Claim 4
Independent Claim
41 words
A method for diagnosing a superantigen-mediated pathological condition, comprising assaying a T-cell containing body fluid sample of a human patient to determine the pattern of Vβ elements present, and identifying the presence of a superantigen-mediated pathological condition from said Vβ pattern.
Claim 5
Independent Claim
37 words
A method for differentiating between superantigen-mediated pathological conditions, comprising assaying a T-cell containing body fluid sample of a human patient to determine the pattern of Vβ elements present, and identifying the specific superantigen mediating the pathological condition.
Claim 6
Independent Claim
37 words
A method for differentiating between superantigen-mediated pathological conditions, comprising assaying a T-cell containing body fluid sample of a human patient to determine the pattern of Vβ elements present, and identifying the specific superantigen mediating the pathological condition.
Claim 7
Dependent Claim
53 words
Method for diagnosing toxic shock syndrome comprising assaying a T-cell containing sample of a human patient to determine a level of Vβ2 subtype T cells in said sample and comparing said level to normals levels in a comparable sample, wherein an increase in said Vβ2 subtype level is indicative of toxic shock syndrome.
Claim 8
Dependent Claim
53 words
Method for diagnosing toxic shock syndrome comprising assaying a T-cell containing sample of a human patient to determine a level of Vβ2 subtype T cells in said sample and comparing said level to normals levels in a comparable sample, wherein an increase in said Vβ2 subtype level is indicative of toxic shock syndrome.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-08-08 | 1998-02-07 | 1998-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-08-08 | 2002-02-07 | 2002-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-08-08 | 2006-02-07 | 2006-08-09 | $7700.00 | Window Closed / Lapsed |